Cargando…

Fixed-Combination Halobetasol Propionate and Tazarotene in the Treatment of Psoriasis: Narrative Review of Mechanisms of Action and Therapeutic Benefits

Psoriasis is a lifelong disease associated with cycles of remission and relapse. Topical treatments are the front line of psoriasis therapy for most patients and have antiproliferative, anti-inflammatory, and immunosuppressive mechanisms of action. Novel fixed-dose combinations of topical therapeuti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lebwohl, Mark G., Tanghetti, Emil A., Stein Gold, Linda, Del Rosso, James Q., Gilyadov, Nelly K., Jacobson, Abby
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8322240/ https://www.ncbi.nlm.nih.gov/pubmed/34106439 http://dx.doi.org/10.1007/s13555-021-00560-6

Ejemplares similares

Impact of Halobetasol Propionate and Tazarotene Lotion 0.01%/0.045% in the Management of Plaque Psoriasis in Adults
por: Reddy, Vidhatha, et al.
Publicado: (2020)

Real-world treatment outcomes with halobetasol propionate 0.01%/tazarotene 0.045% lotion in patients with mild-to-moderate plaque psoriasis: A Canadian multicenter retrospective chart review
por: Vender, Ronald, et al.
Publicado: (2022)

Matching-Adjusted Indirect Comparison of Long-Term Efficacy and Safety Outcomes for Calcipotriol Plus Betamethasone Dipropionate Foam Versus Halobetasol Proprionate Plus Tazarotene Lotion in the Treatment of Plaque Psoriasis
por: Adam, David N., et al.
Publicado: (2022)

Effect of Different Skin Penetration Promoters in Halobetasol Propionate Permeation and Retention in Human Skin
por: Carvajal-Vidal, Paulina, et al.
Publicado: (2017)

Safety and efficacy of tazarotene foam for the treatment of acne vulgaris
por: Epstein, Erica L, et al.
Publicado: (2013)

Halobetasol propionate lotion 0.05% in patients 12 to 16 years 11 months of age with plaque psoriasis: Results of an open-label study evaluating adrenal suppression potential
por: Laquer, Vivian, et al.
Publicado: (2021)

Tazarotene gel with narrow-band UVB phototherapy: a synergistic combination in psoriasis
por: Dayal, Surabhi, et al.
Publicado: (2018)

Moderate and Severe Inflammatory Acne Vulgaris Effectively Treated with Single-Agent Therapy by a New Fixed-Dose Combination Adapalene 0.3 %/Benzoyl Peroxide 2.5 % Gel: A Randomized, Double-Blind, Parallel-Group, Controlled Study
por: Stein Gold, Linda, et al.
Publicado: (2016)

Tazarotene as alternative topical treatment for onychomycosis
por: Campione, Elena, et al.
Publicado: (2015)

Malignancy Rates in Brodalumab Clinical Studies for Psoriasis
por: Gottlieb, Alice, et al.
Publicado: (2020)

A review of tazarotene in the treatment of photodamaged skin
por: Ogden, Stephanie, et al.
Publicado: (2008)

Use of tazarotene foam for the treatment of acne vulgaris
por: Gregoriou, Stamatis, et al.
Publicado: (2014)

EVALUATION OF TOPICAL 0.1% TAZAROTENE CREAM IN THE TREATMENT OF PALMOPLANTAR PSORIASIS: AN OBSERVER-BLINDED RANDOMIZED CONTROLLED STUDY
por: Mehta, Bijal H, et al.
Publicado: (2011)

Tazarotene-Induced Gene 3 May Affect Inflammatory Angiogenesis in Psoriasis by Downregulating Placental Growth Factor Expression
por: Jeon, Su-Young, et al.
Publicado: (2014)

Narrative Review of the Emerging Therapeutic Role of Brodalumab in Difficult-to-Treat Psoriasis
por: Menter, Alan, et al.
Publicado: (2022)

Editorial: fixed‐dose combination calcipotriol/betamethasone dipropionate foam in the treatment of patients with psoriasis
por: Lebwohl, M., et al.
Publicado: (2021)

A phase 1 study of tazarotene in adults with advanced cancer
por: Jones, P H, et al.
Publicado: (2003)

Successful treatment of median canaliform nail dystrophy with topical tazarotene foam
por: Quan, Eugenie Y., et al.
Publicado: (2022)

Photostability Testing of a Third-Generation Retinoid—Tazarotene in the Presence of UV Absorbers
por: Kryczyk-Poprawa, Agata, et al.
Publicado: (2020)

A Case of Pincer Nail Successfully Treated with Tazarotene 0.1% Gel
por: Vollono, Laura, et al.
Publicado: (2020)

Drug screening identifies tazarotene and bexarotene as therapeutic agents in multiple sulfatase deficiency
por: Schlotawa, Lars, et al.
Publicado: (2023)

US Perspectives in the Management of Psoriasis and Psoriatic Arthritis: Patient and Physician Results from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey
por: Lebwohl, Mark G., et al.
Publicado: (2015)

Addressing challenges associated with long‐term topical treatment and benefits of proactive management in patients with psoriasis
por: Lebwohl, M., et al.
Publicado: (2021)

Efficacy and Safety of a Fixed-Dose Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel for Moderate-to-Severe Acne: A Randomized Phase II Study of the First Triple-Combination Drug
por: Stein Gold, Linda, et al.
Publicado: (2021)

BOWENOID PAPULOSIS OF THE GENITALIA SUCCESSFULLY TREATED WITH TOPICAL TAZAROTENE: A REPORT OF TWO CASES
por: Shastry, Veeranna, et al.
Publicado: (2009)

Clinical Efficacy and Safety of Psoriasis Treatments in Patients with Concomitant Metabolic Syndrome: A Narrative Review
por: Merola, Joseph F., et al.
Publicado: (2022)

Tazarotene-Induced Gene 1 Enhanced Cervical Cell Autophagy through Transmembrane Protein 192
por: Shyu, Rong-Yaun, et al.
Publicado: (2016)

Tazarotene-Induced Gene 1 Interacts with DNAJC8 and Regulates Glycolysis in Cervical Cancer Cells
por: Wang, Chun-Hua, et al.
Publicado: (2018)

Safety of IL-23 p19 Inhibitors for the Treatment of Patients With Moderate-to-Severe Plaque Psoriasis: A Narrative Review
por: Blauvelt, Andrew, et al.
Publicado: (2023)

Psoriasis: Overview and Diagnosis
por: Kimmel, Grace W., et al.
Publicado: (2018)

Pustular Psoriasis: A Narrative Review of Recent Developments in Pathophysiology and Therapeutic Options
por: Menter, Alan, et al.
Publicado: (2021)

Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam in Patients with Moderate-to-Severe Psoriasis: Sub-Group Analysis of the PSO-ABLE Study
por: Paul, Carle, et al.
Publicado: (2017)

Microsponge based gel as a simple and valuable strategy for formulating and releasing Tazarotene in a controlled manner
por: Khattab, Alaa, et al.
Publicado: (2022)

Tackling acne vulgaris by fabrication of tazarotene-loaded essential oil-based microemulsion: In vitro and in vivo evaluation
por: Badawi, Noha M., et al.
Publicado: (2023)

Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II Study
por: Lebwohl, Mark G., et al.
Publicado: (2019)

GelMA/PEGDA microneedles patch loaded with HUVECs-derived exosomes and Tazarotene promote diabetic wound healing
por: Yuan, Meng, et al.
Publicado: (2022)

Psoriasis and metabolic syndrome: implications for the management and treatment of psoriasis
por: Wu, J.J., et al.
Publicado: (2022)

PSO-LONG: Design of a Novel, 12-Month Clinical Trial of Topical, Proactive Maintenance with Twice-Weekly Cal/BD Foam in Psoriasis
por: Stein Gold, Linda, et al.
Publicado: (2020)

Tazarotene-induced gene 1 inhibits prostaglandin E2-stimulated HCT116 colon cancer cell growth
por: Tsai, Fu-Ming, et al.
Publicado: (2011)

Brodalumab to the Rescue: Efficacy and Safety of Brodalumab in Patients with Psoriasis and Prior Exposure or Inadequate Response to Biologics
por: Menter, Alan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_hbauidjco46gljof84c82ab1cv